New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole;   - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole   excipient: calcium stearate colloidal silicon dioxide crospovidone hyprolose methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose opadry yellow 03b22011 polysorbate 80 sodium carbonate sodium laurilsulfate triethyl citrate - for the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer (du)

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole;  ;   - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole     excipient: calcium stearate crospovidone mannitol methacrylic acid copolymer opadry yellow oy-52945 povidone purified water   sodium carbonate triethyl citrate - 1. for the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: - duodenal ulcer

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole;   - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole   excipient: calcium stearate crospovidone mannitol methacrylic acid copolymer opadry yellow oy-52945 povidone purified water   sodium carbonate triethyl citrate - short-term symptomatic relief of gastric reflux-like symptoms in patients aged 18 years and over.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole;   - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to 20 mg pantoprazole   excipient: calcium stearate colloidal silicon dioxide crospovidone hyprolose ink methacrylic acid - ethyl acrylate copolymer microcrystalline cellulose opadry yellow 03b22011 polysorbate 80 sodium carbonate sodium laurilsulfate triethyl citrate - suvacid heartburn relief is indicated for the short term, symptomatic relief of gastric, reflux-like symptoms in sufferers aged 18 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hyprolose; crospovidone; triethyl citrate; sodium carbonate; microcrystalline cellulose; colloidal anhydrous silica; calcium stearate; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; hypromellose; iron oxide yellow; quinoline yellow aluminium lake; macrogol 400; brilliant scarlet 4r aluminium lake - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastro-oesophageal reflux disease (gord) i. symptomatic gord. the treatment of heartburn and other symptoms associated with gord ii. reflux oesophagitis; gastrointestinal lesions refractory to h2 blockers ; zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxicillin or; clarithromycin and metronidazole or; amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - pantoprazole sodium sesquihydrate 22.55mg equivalent to pantoprazole base 20 mg - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to pantoprazole base 20 mg excipient: calcium stearate crospovidone hyprolose mannitol methacrylic acid - ethyl acrylate copolymer   opacode black s-1-27794 opadry yellow oy-52945 purified talc   sodium carbonate titanium dioxide triethyl citrate zein - 1. for the symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: · duodenal ulcer · gastric ulcer · gastro-oesophageal reflux disease (gord) - for the treatment of mild reflux disease and associated symptoms (e.g. heartburn, acid regurgitation, pain on swallowing) - reflux oesophagitis · zollinger-ellison syndrome 2. eradication of helicobacter pylori (hereinafter referred to as h. pylori) in combination with · clarithromycin and amoxycillin or · clarithromycin and metronidazole or · amoxycillin and metronidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism. 3. prevention of gastroduodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (nsaids) in patients at risk with a need for continuous nsaid treatment.

United States - English - NLM (National Library of Medicine)

direct rx - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: 1.1 short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (gerd) pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 maintenance of healing of erosive esophagitis pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. 1.3 pathological hypersecretory conditions including zollinger-ellis

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.55 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; sodium carbonate; triethyl citrate; calcium stearate; hyprolose; crospovidone; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; hypromellose; iron oxide yellow; quinoline yellow aluminium lake; macrogol 400; brilliant scarlet 4r aluminium lake - 1. for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: duodenal ulcer; gastric ulcer; gastro-oesophageal reflux disease (gord) i. symptomatic gord. the treatment of heartburn and other symptoms associated with gord ii. reflux oesophagitis; gastrointestinal lesions refractory to h2 blockers ; zollinger-ellison syndrome. patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxicillin or; clarithromycin and metronidazole or; amoxicillin and metronidazole - is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this micro-organism. 4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism. 5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - pantoprazole sodium sesquihydrate 22.55mg equivalent to pantoprazole base 20 mg - enteric coated tablet - 20 mg - active: pantoprazole sodium sesquihydrate 22.55mg equivalent to pantoprazole base 20 mg excipient: calcium stearate crospovidone hyprolose mannitol methacrylic acid - ethyl acrylate copolymer   opacode black s-1-17823 opadry yellow oy-52945 purified talc   sodium carbonate titanium dioxide triethyl citrate zein - short-term, symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pediatric indication and usage information in pediatric patients ages 5 years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals inc.’s pantoprazole sodium delayed-release tablets. however, due to wyeth pharmaceuticals inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartbu